Answers are grounded in this paper and cite their sources.
Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1–receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.
No takes yet. Share an insight, caveat, or question.
Pfeffer et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: